Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,769Revenue $M73.7Net Margin (%)347Altman Z-Score4.9
Enterprise Value $M1,784EPS $12.0Operating Margin %35.2Piotroski F-Score5
P/E(ttm)7.4Beneish M-Score-0.0Pre-tax Margin (%)49.5Higher ROA y-yY
Price/Book6.110-y EBITDA Growth Rate %--Quick Ratio12.9Cash flow > EarningsN
Price/Sales25.45-y EBITDA Growth Rate %--Current Ratio12.9Lower Leverage y-yY
Price/Free Cash Flow137y-y EBITDA Growth Rate %51.7ROA % (ttm)79.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)274Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M19.9ROIC % (ttm)252Gross Margin Increase y-yN

Gurus Latest Trades with LGND

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDKen Fisher 2015-12-31 Reduce$85.69 - $111.85
($99.19)
$ 88.79-10%Reduce -0.14%70,583
LGNDKen Fisher 2015-09-30 Reduce$82.1 - $111.25
($97.26)
$ 88.79-9%Reduce -12.31%70,683
LGNDKen Fisher 2015-06-30 Reduce$75.67 - $100.9
($87.3)
$ 88.792%Reduce -1.59%80,608
LGNDJoel Greenblatt 2015-03-31 Sold Out -0.0016%$51.54 - $77.11
($61.42)
$ 88.7945%Sold Out0
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 88.7970%Reduce -99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 88.7970%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 88.7967%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 88.7936%New holding55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 88.7936%New holding36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 88.7934%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 88.7970%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 88.7996%New holding6,136
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 88.79574%Sold Out0
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 88.79742%New holding10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.14)
$ 88.79631%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.16)
$ 88.79449%New holding4,483
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KOZARICH JOHN WDirector 2016-01-20Sell1,666$94.94-6.48view
Aryeh JasonDirector 2015-11-11Sell3,000$101.49-12.51view
Herman Melanie JDirector of Accounting 2015-11-11Sell7,719$101-12.09view
KNOTT DAVID MDirector 2015-08-17Sell4,000$95.98-7.49view
KNOTT DAVID MDirector 2015-08-13Sell49,800$96.26-7.76view
KNOTT DAVID MDirector 2015-08-07Sell200$99.02-10.33view
HIGGINS JOHN LCEO 2015-08-06Sell4,666$110.79-19.86view
Berkman Charles SVP, Gen. Counsel & Secretary 2015-07-10Sell14,067$99.14-10.44view
FOEHR MATTHEW WPresident and COO 2015-06-26Sell12,500$100.97-12.06view
FOEHR MATTHEW WPresident and COO 2015-06-22Sell23,046$96.45-7.94view

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Ligand Pharmaceuticals (LGND): Q4 Earnings Preview Feb 08 2016
Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics Feb 02 2016
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : January 27, 2016 Jan 27 2016
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : January 27,... Jan 27 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 26 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 22 2016
Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th Jan 22 2016
Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th Jan 22 2016
These 2 Small-Cap Stocks Could Add Powerful Returns to Your Portfolio Jan 18 2016
Ligand, Emergent BioSolutions Tie Up for OmniAb Technology Jan 14 2016
Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions Jan 13 2016
Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions Jan 13 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jan 08 2016
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and... Jan 08 2016
5 Biotech Stocks That Doubled in 2015 Jan 07 2016
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 5,... Jan 05 2016
[$$] Ligand's Gilead Pact a Harbinger for Growth Dec 31 2015
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 31 2015
Emerging from shadows, pot industry tries to build brands Dec 30 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK